| Study |
Description |
Status |
|---|
Pre-Clinical & Basic Research
AIDS Research Alliance |
AIDS Research Alliance is engaged in a number of ongoing preclinical and basic research projects. |
Ongoing |
KP-1461
Koronis Pharmaceuticals, Inc. |
A study to investigate the safety, tolerability, and pharmacokinetics of multiple oral doses of KP-1461 in HIV-positive volunteers who have failed two or more Highly Active Antiretroviral (HAART) regiments. (antiviral therapy) |
Enrollment pending |
Pregabalin A0081066
Pfizer |
A trial to investigate the efficacy and safety of pregabalin versus a placebo in the treatment of neuropathic pain in HIV-positive volunteers.
(pain alleviation) |
Enrollment pending |
TMC114
Tibotec |
A study to compare the efficacy, safety, and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected volunteers. (antiviral therapy) |
Enrollment & study ongoing |
TH9507 (Growth Hormone)
Theratechnologies Inc. |
A study to assess the efficacy and safety of TH9507, a growth hormone releasing factor analog, in HIV-positive volunteers with an excess of abdominal fat accumulation.
(fat redistribution therapy) |
Enrollment & study ongoing |
HIV SpectraPoint
SpectraDigital Corporation |
A Phase I pilot, proof-of-concept study to determine the efficacy of an in vitro diagnostic device, HIV SpectraPoint, in HIV positive volunteers with prior resistance to antiretroviral medications. (testing device) |
Enrollment & study ongoing |
Microbial Food Supplement
AIDS Research Alliance &
Alimentary Health, Ltd |
A randomized, double-blind, placebo-controlled study of the safety and efficacy of Bifidobacterium infantis therapy in the treatment of HIV-1 associated diarrhea.
(anti-diarrhea therapy) |
Enrollment & study ongoing |
Investigational HIV-1 Vaccine
Major Pharmaceutical Co. |
A study testing the safety, tolerability, and efficacy of an investigational HIV-1 vaccine in healthy volunteers at higher risk of HIV infection. (preventative vaccine) |
Enrollment & study ongoing |
Investigational HIV-1 Vaccine
Major Pharmaceutical Co. |
A study testing the safety, tolerability, and efficacy of an investigational HIV-1 vaccine in healthy volunteers at low risk of HIV infection. (preventative vaccine) |
Enrollment & study ongoing |
BMS AI424128
Bristol-Myers Squibb |
A study to evaluate 150L substitution among treatment-experienced HIV positive volunteers who have failed Highly Active Antiretroviral (HAART) regimens containing Atazanavir (ATV). |
Enrollment & study ongoing |
CCR5-HV01
Human Genome Sciences, Inc. |
A Phase I, randomized, placebo-controlled, single injection, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CCR5mAb004 (human monoclonal IgG4 antibody to CCR5) in HIV-1 seropositive individuals who are not receiving concurrent antiretroviral therapy. (antiviral therapy) |
Enrollment complete; study ongoing |
Investigational Integrase Inhibitor
Major Pharmaceutical Co. |
A study to compare the safety and activity of an investigational integrase inhibitor in combination regimens with 2 approved antiviral drugs, compared to a standard 3 drugs combination in antiretroviral-na�ve HIV-infected volunteers.
(antiviral therapy) |
Enrollment complete; study ongoing |
Investigational Integrase Inhibitor
Major Pharmaceutical Co. |
A study to compare the safety and activity of an investigational integrase inhibitor in combination regimens with optimized background treatment, compared to optimized background therapy alone, in antiretroviral-experienced HIV-infected volunteers with documented resistance to one of the antiretroviral drug in each class.
(antiviral therapy) |
Enrollment complete; study ongoing |
AI424103
Bristol-Myers Squibb |
A Phase IIIB, open-label, randomized, multi-center study comparing the antiviral efficacy, safety and effect on serum lipids of atazanavir/ritonavir versus lopinavir/ritonavir, each in combination with tenofovir and either didanosine EC or stavudine XR in HIV-1 infected subjects receiving an NNRTI-containing HAART regimen who are experiencing their first virologic failure. (antiviral therapy) |
Enrollment complete; study ongoing |
